Global Prostate Cancer Diagnostics Market Size & Share to 2027

Global Prostate Cancer Diagnostics Market Size & Share to 2027

Global Prostate Cancer Diagnostics Market Size, Trends & Growth Opportunity, By Type (Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Others), By Diagnosis (Tissue Biopsy, Transrectal Ultrasound, Clinical Laboratory Examination, Urine Testing, and Prostate Specific Antigen Testing), By Treatment, By Region and Forecast till 2027

Global Prostate Cancer Diagnostics Market

Prostate gland is situated in the pelvis below the bladder. Prostate cancer is the medical condition which is an unbounded and unusual growth of cells in the prostate glands of the male. Growth of healthcare expenditure and innovation of new technologies in minimally invasive surgeries to patients due to early post-operative recovery are also likely to driven the global prostate cancer diagnostics market growth.

Market Drivers

Rise in prevalence of prostate cancer is key driving factor which is expected boost the global prostate cancer diagnostics market growth. For instant, as per the National Cancer Institute in United State around 174,650 new cases were diagnosed in year 2019. Furthermore, growing technological advancements in diagnostic tests are expected to further propel the global prostate cancer diagnostics market growth over the forecast period. Also, increase in government support and initiatives to develop new technologies to enhance diagnosis will positively influence the market growth. The increase in number of number of new market entrants is another driving factor anticipated to drive the market growth in near future. In addition to that, increase in product approvals by USFDA is projected to support the global prostate cancer diagnostics market growth.

Market Restraints

The high cost of prostate cancer drugs is the major restrain which is expected to hinder the global prostate cancer diagnostics market growth. Also, low success rate of clinical trials will affect the global prostate cancer diagnostics market growth over the forecast period.

Market Segmentation

Global Prostate Cancer Diagnostics Market is segmented into type such as Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Others, by diagnosis, such as Tissue Biopsy, Transrectal Ultrasound, Clinical Laboratory Examination, Urine Testing, and Prostate Specific Antigen Testing. Further, market is segmented into treatment such as Surgery, Radiation Therapy, and Therapeutics (Hormone Therapy, Chemotherapy, and Others).

Also, Global Prostate Cancer Diagnostics Market is segmented five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Market Key Players

Various key players are discussed in this report including Abbott, MDxHealth, Genomic Health, 3D Signatures, OPKO Health, INC., Siemens Healthcare GmbH, DiaSorin S.p.A, F. Hoffman La Roche Ltd., BioMerieux SA, Beckman Coulter, INC., and Myriad Genetic Inc.

Market Taxonomy

By Type

• Benign Prostatic Hyperplasia
• Prostatic Adenocarcinoma
• Small Cell Carcinoma
• Others

By Diagnosis

• Tissue Biopsy
• Transrectal Ultrasound
• Clinical Laboratory Examination
• Urine Testing
• Prostate Specific Antigen Testing

By Treatment

• Surgery
• Radiation Therapy
• Therapeutics

 Hormone Therapy

 Chemotherapy

 Others

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Key Questions Addressed by the Report

• What are the Key Opportunities in Global Prostate Cancer Diagnostics Market?
• What will be the growth rate from 2019 to 2027?
• Which segment/region will have highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
• What are the strategies adopted by key players?